Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8294071 | 0.91 | POLB (0.55) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15082401 | 0.90 | POLB (0.53) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15082397 | 0.88 | L3MBTL1 (0.51) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1280029 | 0.86 | POLB (0.50) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8294064 | 0.85 | POLB (0.55) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15082390 | 0.84 | POLB (0.48) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2892450 | 0.83 | L3MBTL1 (0.60) | CYP2C19RECQLKMT2APOLBSMN1; SMN2 | |
| SCHEMBL8293341 | 0.83 | L3MBTL1 (0.60) | CYP2C19RECQLKMT2APOLBSMN1; SMN2 | |
| SCHEMBL8292876 | 0.82 | POLB (0.58) | CYP2C19KMT2APOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL15082388 | 0.82 | POLB (0.58) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | CYP2C19 1381/4885CYP1A2 1450/4885CYP3A4 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.